Crossover ETFs sell private growth the wrapper cannot price

Fifteen is the number that governs the pre-IPO ETF: an open-end fund generally cannot hold more than 15% of net assets in investments the SEC classifies as illiquid, so a crossover strategy that wants daily-priced, redeemable shares has to keep 85% or more of its book in public equities and spend the rest on late-stage venture rounds or secondary-market pre-IPO stock. Everything the category sells — the crossover funds, the interval-fund hybrids, the active public-private ETFs — comes down to an argument about what that residual sleeve should hold.

Companies are staying private longer, and the growth that once reached public shareholders through an IPO now largely happens before the listing. Issuers have answered with a menu built for retail and advisor accounts: crossover strategies, interval hybrids that take limited redemptions, and active public-private ETFs, with AI and aerospace as the sectors where late-stage private valuations have run furthest ahead of any listing timetable.

The most direct version of the trade, and now the best-known, is the crossover fund: KraneShares' Artificial Intelligence & Technology ETF, AGIX, made headlines in March 2025 as one of the first U.S.-listed ETFs to buy straight into a private company, taking a stake in Anthropic that has run in the 4% to 5% range of net assets as a direct shareholder. ERShares' Private-Public Crossover ETF, XOVR, works the same idea from the other side, pairing a large-cap public equity core with a private sleeve built through special purpose vehicles — a sleeve previously concentrated almost entirely in SpaceX, with smaller positions in Anduril and the prediction-markets operator Kalshi.

Set the two prospectuses side by side and the wrappers look alike: a conventional public equity portfolio of ordinary size and behavior, plus a sliver of an asset with no daily price and no market to check it against. The shares are liquid even though the exposure the buyer came for has no daily price at all, which is defensible inside the 15% line but decides what the product is — the pitch reads like marketing for a private-market fund stapled to a public-market one.

Advisor appetite for that staple has been real rather than hypothetical. This publication's August look at RIA ETF flows found the quarter's net additions landing in tech, semiconductors, and a crossover fund tied to SpaceX, which suggests the bid for private-company exposure is arriving through allocation data rather than issuer roadshows alone. The wrapper itself is the appeal: a pre-IPO sleeve trades and settles like any other ETF, so it drops into a model portfolio beside a semiconductor fund instead of requiring a subscription document, a lockup, or an accreditation check.

Aerospace has taken the concentration further: Baron's First Principles ETF, RONB, and the Procure Space ETF, UFO, have both drawn asset growth by holding SpaceX alongside listed equities, and RONB's allocation has periodically topped 30% of net assets — enough that a fund sold as diversified becomes, at the top of that range, one private company's financing story. Benchmark providers are accommodating the shift rather than resisting it: earlier this year the VettaFi Space Index added a fast-track rule to admit newly public space firms right after their IPOs, shortening the gap between a private holding and a priced one.

Not every issuer is willing to carry the mark itself; some are exploring synthetic exposure, using swaps and derivative overlays to copy the economics of private-company ownership without holding illiquid shares outright, which likely shifts the valuation question from the fund's pricing process to a counterparty's — cleaner disclosure, different risk, and no smaller a judgment call.

The unsolved piece is the one the trade-offs in this category tend to gloss over: an ETF prints a net asset value daily and trades all session, while the private sleeve is marked on a schedule that has nothing to do with the market's, so when the public 85% moves, the sleeve can sit still and the reported NAV drifts from any defensible read on what the fund owns. That is the price of putting an unlisted company inside a listed wrapper, and no issuer has argued it away.

Anthropic is where the test arrives next: the company is the subject of a live IPO filing, and this publication has written that a debut could value it near $1 trillion — a listing that would do what no pricing committee can, turning the crossover sleeve into a market price on the first day shares trade. For AGIX that is a 4% to 5% position getting its first public print; for every rival holding a late-stage name, it is a reference point the whole shelf will be measured against.

Active management's broader migration into the ETF wrapper has always been a story about distribution. The crossover fund is the sharpest case yet: liquid, fractional, quotable, easy for an advisor to explain — while the exposure that justifies the story sits in a sleeve small enough that a single company's financing round can carry the whole narrative. That is not alpha finding a new wrapper so much as a distribution format that finally found the right subject.

Watch the first NAV print after Anthropic prices. The 15% line is fixed, the liquid 85% is unremarkable, and the sleeve in between is where the category gets judged — on a number the issuers will not get to set.